Results 201 to 210 of about 7,490 (233)
Some of the next articles are maybe not open access.
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia
Seminars in Oncology, 2016Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and remains incurable outside of the setting of allogeneic stem cell transplant. While the standard therapy for both initial and relapsed CLL has traditionally included monoclonal antibody therapy in combination with chemotherapy, there are patients with high-risk disease features ...
Kami, Maddocks, Jeffrey A, Jones
openaire +2 more sources
Genetic Variation in Bruton Tyrosine Kinase
2015X-linked agammaglobulinemia (XLA) is a hereditary immunodeficiency caused by variations in the gene encoding for Bruton’s tyrosine kinase (BTK). Patients with XLA have decreased numbers of mature B cells, lack all immunoglobulin isotypes, and therefore have susceptibility to severe bacterial infections. XLA-causing variations are collected into BTKbase
Gerard C. P. Schaafsma, Mauno Vihinen
openaire +1 more source
Next-Generation Bruton Tyrosine Kinase Inhibitors
Journal of Clinical Oncology, 2020Deborah M, Stephens, John C, Byrd
openaire +2 more sources
Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis
British Journal of PharmacologyAbstractBackground and PurposePathological retinal angiogenesis is a typical manifestation of vision‐threatening ocular diseases. Many patients exhibit poor response or resistance to anti‐vascular endothelial growth factor (VEGF) agents. Bruton's tyrosine kinase (BTK) controls the proliferation and function of immune cells.
Siyue Chen +11 more
openaire +2 more sources
Bruton's tyrosine kinase in systemic lupus erythematosus
Joint Bone Spine, 2020Hsien-Tzung Liao +4 more
openaire +2 more sources
Treatment of renal cell carcinoma: Current status and future directions
Ca-A Cancer Journal for Clinicians, 2017Pedro Coelho Barata, Brian I Rini
exaly
Lung cancer: New biological insights and recent therapeutic advances
Ca-A Cancer Journal for Clinicians, 2011Suresh S Ramalingam, Fadlo R Khuri
exaly